Who is winning the biotech endgame?
Article Abstract:
Small biotechnology companies face difficulties in surviving since they usually have five or fewer drugs being tested, and only a tenth of drugs that survive Phase 1 trials become drugs that are prescribed to patients. The problems of British Biotech in 1998 affected stock prices for the United Kingdom biotech sectors as a whole. Risks and development costs are high, but rewards can also be high. Some companies have performed well, and they include Shire Phamaceuticals, which is merging with Roberts. Investors should invest in a number of stocks and keep updated with events in the sector.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Will the biotechnology bubble burst
Article Abstract:
Share prices for biotechnology companies have risen, but there are risks involved in investing in this sector. There is the risk of failure in seeking to develop new drugs, and only some 10% are sold commercially of those which reach the inital phase of tests involving humans. Successes can bring great rewards since large pharmaceutical companies will pay high prices for successful drugs. Investors may find that prices have risen too high by 1996, though some analysts argue that the rise has been from a low base and could thus continue.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Drugs firms look to mergers as cash squeeze cramps industry
Article Abstract:
Biotechnology companies are likely to be affected by a large number of acquisitions and mergers, and some smaller companies have already announced deals. Therapeutics Antibodies and Proteus International plan to merge, while Valentis is to acquire Polymasc Pharmaceuticals. Many companies are seeking partners due to lack of cash, and are unable to raise funds through issuing stocks due to their low stock prices. Companies that could attract bidders include Cortecs, and Cambridge Antibody Technology.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Moving with the times. Tricks of the trust trade. Trusting the young ones
- Abstracts: Workers unite: the unions are back. Time to get loaded
- Abstracts: A matter of appreciating depreciation. Deferred tax - a case for consistency. Fixed assets: costs, lives and depreciation
- Abstracts: Avoiding the burden of gilts. Investors should go it alone with gilts
- Abstracts: Rescue on hold. The discreet charms of private banking. Modest beginnings but growing all the time